Related Experiment Video
Updated: Mar 28, 2026

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Extensions of indication throughout the drug product lifecycle: a quantitative analysis
Joris Langedijk1, Christopher J Whitehead1, Diederick S Slijkerman2
1Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands; Medicines Evaluation Board, Utrecht, The Netherlands.
Abstract:
The marketing authorisation of the first generic product version is an important moment in a drug product lifecycle. The subsequently changed intellectual property protection prospects could affect the incentives for further drug development. We assessed the quantity and nature of extensions of indication of small molecule medicinal products authorised through the European Medicines Agency throughout the drug product lifecycle with special attention for the impact of the introduction of a first generic competitor. The majority (92.5%) of the extensions of indication was approved during the exclusivity period of the innovator product. Regulatory rethinking might be needed for a sustainable stimulation of extensions of indications in the post-generic period of a drug product lifecycle.
Related Concept Videos
Clinical Trials: Overview
Drug Product Performance: In Vitro–In Vivo Correlation
Clinically Relevant Drug Product Specifications: Methods of Establishment
Therapeutic Drug Monitoring: Drug Analysis Methods
Analysis of Population Pharmacokinetic Data
Biopharmaceutical Factors Influencing Drug Product Design: Overview

